Abstract
Background Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have been associated with lower rates of pancreatic cancer. However, some studies did not similarly reveal significant associations. The objective of this study was to examine the associations between use of ACEIs or ARBs and incident pancreatic cancer.
Methods Patients who were prescribed ACEI or ARB between 1 January 2000 and 31 August 2020 at Hong Kong public hospitals, or their associated clinics and ambulatory care facilities were included. The primary outcome was incident pancreatic cancer.
Results A total of 411,883 patients (ACEI users: n=355771, 86.38%; ARB users: 56112, 13.62%) were included. Over a median follow up of 2875 days (SD: 1901), 1194 incident cases of pancreatic cancer (0.28%) were identified. After 1:1 propensity score matching, univariable Cox regression found that ARB use was associated with lower risks of new onset new onset pancreatic cancer (hazard ratio [HR]: 0.69, 95% CI: [0.53, 0.90], P=0.0065). This association remained significant after multivariable adjustment (HR: 0.67, 95% CI: [0.52, 0.88], P=0.0036). Similar conclusions were reached on competing risk analyses using cause-specific and subdistribution hazard models before and after matching, and after inverse probability of treatment weighting. Subgroud analyses identified higher protective effects of ARB exposures in females than in males, while more severe adverse risks of ACEI exposure effects for males than for females (log-rank test, P<0.05).
Conclusions ARB use was associated with lower risks of new onset pancreatic cancer both before and after propensity score matching compared to ACEI use.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by The Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster and The Joint Chinese University of Hong Kong/New Territories East Cluster Clinical Research Ethics Committee.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* joint first authors
Data Availability
All data produced in the present study are available upon reasonable request to the authors